Market Research Report
Investigation Report on China Tiotropium Bromide Market, 2010-2019
|Published by||China Research and Intelligence||Product code||297269|
|Published||Content info||20 Pages
Delivery time: 1-2 business days
|Investigation Report on China Tiotropium Bromide Market, 2010-2019|
|Published: June 4, 2015||Content info: 20 Pages||
In recent years, various allergic diseases demonstrate an increasing trend under the influence of global environmental changes, leading to the occurrence of seasonal cough and asthma in winter and spring. Affected by tobacco, dust and pollutants, the incidence of chronic obstructive pulmonary disease (COPD) is still on the rise. COPD is a chronic pulmonary disease characterized by incompletely reversible airflow obstruction. The major clinical manifestations are recurrent cough, expectoration, dyspnea. COPD often demonstrate a progressive characteristic, including large parts of chronic bronchitis and emphysema.
According to a survey, the incidence of COPD among people aged above 40 is 8.2% on average and higher in men (12.4%) than in women (5.1%). The number of COPD cases in China has exceeded 40 million and 65 million people are expected to die of COPD during the period of 2003-2033.
For many years, the COPD market and anti-asthmatic agents market have been dominated by four big companies - GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca and Merck. They take up over 80% of respiratory agents market around the world while Novartis, Roche and Teva only occupy about 10%.
Tiotropium bromide, a long-acting anticholinergic drug for inhalation, was developed by Boehringer Ingelheim. It is the first inhaler that can offer significant and lasting lung function improvement after one dosage per day. Tiotropium bromide can exert positive influence on COPD's clinical course so as to help improve the state of patient's life. Therefore it is widely welcomed by patients and has become the drug with the largest prescriptions in the world for the treatment of COPD. The sales value of tiotropium bromide in global market in 2013 reached nearly USD 5 billion.
According to CRI's survey, tiotropium bromide develops fast after entering China with annual sales rising from less than CNY 1 million in 2006 to CNY 140 million in 2014 and CAGR reaching up to 90% during the period of 2006-2014. Currently, Tiotropium bromide in the Chinese market comes from the following three companies: Boehringer Ingelheim (Germany), Chia Tai Tianqing Pharmaceutical Group Co., Ltd, Zhejiang Xianju Pharmaceutical Co., Ltd, among which Boehringer Ingelheim (Germany) has the largest market share of over 80% with sales value reaching up to CNY 114 million in 2014.
It is expected that in the next few years, tiotropium bromide market in China will keep expanding fast.
Readers can get at least the following information through this report:
The author suggests the following groups of people purchase this report: